The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using chemo- and radio-therapy modestly increases the overall survival of patients; however, recurrence is inevitable, due to treatment resistance and lack of response to targeted therapies. GBM therapy resistance has been attributed to several extrinsic and intrinsic factors which affect the dynamics of tumor evolution and physiology thus creating clinical challenges. Tumor-intrinsic factors such as tumor heterogeneity, hypermutation, altered metabolomics and oncologically activated alternative splicing pathways change the tumor landscape to facilitate therapy failure and tumor progression. Moreover, tumor-extrinsic factors such as hypoxia and an immune-suppressive tumor microenvironment (TME) are the chief causes of immunotherapy failure in GBM. Amid the success of immunotherapy in other cancers, GBM has occurred as a model of resistance, thus focusing current efforts on not only alleviating the immunotolerance but also evading the escape mechanisms of tumor cells to therapy, caused by inter- and intra-tumoral heterogeneity. Here we review the various mechanisms of therapy resistance in GBM, caused by the continuously evolving tumor dynamics as well as the complex TME, which cumulatively contribute to GBM malignancy and therapy failure; in an attempt to understand and identify effective therapies for recurrent GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most tumors are poorly vascularized and hypoxic, which advances cancer progression and chemoresistance [70, 71].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · cited 9×
“Increasing mitochondrial ROS (mROS) has also been investigated to sensitize cells to RT. Post-radiation, the Hypoxia Inducible Factor 1α (HIF1α) target gene pyruvate dehydrogenase kinase (PDK) has been shown to be upregulated.”
BackgroundInfluentialSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Next, earlier studies have shown that TMZ is a direct cause of hypermutation in recurrent gliomas as seen by the accumulation of a TMZ-specific mutational signature in these tumors [39,62].”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668 · cited 1×
“Gliomas with methylated MGMT promoters are more sensitive to TMZ‐in‐ duced cytotoxicity with a longer median overall survival, as compared to patients whose tumors have unmethylated MGMT promoters [5,6].”
BackgroundVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 2×
“TAMs are the dominant infiltrating immune population in glioma constituting around 30–40% of the total tumor volume [25,132,138].”
BackgroundSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 1×
“The GBM TME attracts TAMs to the tumor and polarizes them to an anti-inflammatory or pro-tumorigenic ‘M2′-like state, thus current studies are aimed at inhibiting their recruitment or survival in the TME, allowing for their functional re-education to an anti-tumor ‘M1′-like state, or targeting the tumor using monoclon…”
Background
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“However, most tumors are poorly vascularized and hypoxic, which advances cancer progression and chemoresistance [70, 71].”
BackgroundSelf-citationGlioma: molecular signature and crossroads with tumor microenvironment
Barthel, L., Hadamitzky, M., Dammann, P., Schedlowski, M., Sure, U., Thakur, B. K., & Hetze, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09997-9 · Cited by 211
The tumour microenvironment, treatment resistance and recurrence in glioblastoma
White, J., White, M. P. J., Wickremesekera, A., Peng, L., & Gray, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05301-9 · Cited by 168
“5) [28, 128].”
BackgroundInfluentialCheng, G., Kwong, C. H. T., Wang, Q., Kam, H., Xie, B., Lee, S. M., Chen, G., & Wang, R. (2023) · ACS Nano · doi:10.1021/acsnano.3c00041 · Cited by 157
Molecular Mechanisms of Drug Resistance in Glioblastoma
Dymova, M. A., Kuligina, E. V., & Richter, V. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126385 · Cited by 152
“If the BBB is disrupted by tumor proliferation or inflammation, then the tumor can be infiltrated by immunosuppressive immune cells [67].”
Background
Metadata
- Authors
- Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Cheng, Shi-Yuan
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-02-24
- Volume
- 10
- Issue
- 3
- Pages
- 484
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7995978
- OpenAlex
- W3132558808
- Cited by
- 169
- References
- 157
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 27 · 2023: 36 · 2022: 26 · 2021: 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (CA221747, CA234799)
- National Institute of Neurological Disorders and Stroke (NS093843, NS095634, NS115403)
- The Lou and Jean Malnati Brain Tumor Institute at Northwestern Medcine (10031379)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glioblastoma, treatment resistance, tumor recurrence, tumor heterogeneity, hypermutation, cancer metabolomics, alternative splicing, hypoxia, tumor microenvironment, immunosuppression, immunotherapy resistance, tumor evolution
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Neoplasm Recurrence, Local, Drug Resistance, Neoplasm, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.